While many are hopeful that 2021 will bring better times than 2020, there’s much we don’t know about what this new year has in store. One thing we do know, points out the author of today’s article, is that “there will be new problems needing more tech, and tech investors are ever-ready to pounce when that time comes.” As such,…
The thing that created the conditions that made 2020 so awful for so many – the coronavirus pandemic – also created the conditions for tech to stage an impressive rally. The three promising tech stocks highlighted in today’s article, however, did not participate in that rally. As a result, these underperforming stocks “still trade at levels that leave room for…
Compelling clinical trial data and decisions from the FDA could send one, two, or all three of the biotech stocks highlighted in today’s article through the roof next year. For a look at each of these three biotech stocks and their respective catalysts – as well as a consideration of the potential pitfalls associated with each of them – CLICK…
“In light of all the focus on a coronavirus vaccine, most people tend to overlook the other happenings in the industry,” notes the author of today’s article. He reminds us that, even in the midst of a global pandemic, research has continued on treatments and drugs for cancers, genetic diseases, rare diseases and more – and he highlights three biotech…
Which biotechs are the hottest acquisition targets heading into 2021 – and which large drugmakers are likely to seek to acquire them? Seventy-eight members of the biopharma investment community offered their opinions in a recent Bloomberg Intelligence survey – and today’s article outlines their biotech acquisition predictions. For more, CLICK HERE.